Similar companies
Income Statement (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Revenue | 200,000 | 219.2% |
| Gross Profit | 160,000 | 777.8% |
| Cost of Revenue | 45,000 | 0% |
| Operating expense | 4.7M | 14.8% |
| Net Income | -3.5M | 15.6% |
| EBITDA | -4M | 2.4% |
Balance Sheet (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Total Assets | 12M | 9.4% |
| Total Liabilities | 5.1M | 14.7% |
| Total Equity | 6.1M | 5.9% |
| Shares Outstanding | 3.7M | 20.6% |
Cash Flow (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Cash from operations | -2.4M | 1.3% |
| Cash from financing | 130,000 | 97.9% |
EPS
Financial Highlights for Coeptis Therapeutics in Q2 '25
Coeptis Therapeutics reported a revenue of 200,000, which is a 219.2% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 160,000, marking a 777.8% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 45,000, a 0% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 4.7M, showing a 14.8% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -3.5M, showing a -15.6% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -4M, showing a 2.4% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Coeptis Therapeutics faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies.
